Authors:
KLIJN J
HAMILTON A
BEEX L
MAURIAC L
PARIDAENS R
ROY JA
AWADA A
VANVRECKEM A
PALMER P
PICCART M
Citation: J. Klijn et al., EORTC-10941 - FINAL RESULTS OF A PHASE-II STUDY OF LIAROZOLE FUMARATEIN PATIENTS WITH METASTATIC BREAST-CANCER, European journal of cancer, 34, 1998, pp. 72-72
Authors:
AWADA A
CUFER T
BEEX L
COLEMAN R
PARIDAENS R
BRUNING P
KLIJN J
NOOIJ M
MAURIAC L
VANVRECKEM A
BIGANZOLI L
PICCART MJ
Citation: A. Awada et al., EORTC-IDBBC (INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER) - 7 YEARSOF ACTIVE EUROPEAN COLLABORATION, European journal of cancer, 34, 1998, pp. 86-86
Authors:
KLIJN JGM
BLAMEY RW
BOCCARDO F
TOMINAGA T
JONAT W
KAUFMANN M
BEEX L
MAURIAC L
HOCTINBOES G
DUCHATEAU L
SYLVESTER R
Citation: Jgm. Klijn et al., A NEW STANDARD TREATMENT FOR ADVANCED PREMENOPAUSAL BREAST-CANCER - AMETAANALYSIS OF THE COMBINED HORMONAL AGENT TRIALISTS GROUP (CHAT), European journal of cancer, 34, 1998, pp. 405-405
Authors:
KLIJN JGM
BEEX L
MAURIAC L
VANZIJL J
VEYRET C
WILDIERS J
JASSEM J
BURGHOUTS J
PICCART M
MIGNOLET F
DUCHATEAU L
Citation: Jgm. Klijn et al., COMBINED TREATMENT WITH THE LHRH-AGONIST BUSERELIN (LHRH-A) AND TAMOXIFEN (TAM) VS SINGLE TREATMENT WITH EACH DRUG ALONE IN PREMENOPAUSAL METASTATIC BREAST-CANCER - FINAL RESULTS OF EORTC-STUDY-10881, Annals of oncology, 9, 1998, pp. 540-540
Authors:
DEWITTE H
SWEEP F
BRUNNER N
HEUVEL J
BEEX L
GREBENSCHIKOV N
BENRAAD T
Citation: H. Dewitte et al., COMPLEXES BETWEEN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND ITS RECEPTOR IN BLOOD AS DETERMINED BY ENZYME-LINKED-IMMUNOSORBENT-ASSAY, International journal of cancer, 77(2), 1998, pp. 236-242
Citation: H. Brink et al., UNUSUAL RETINAL-PIGMENT EPITHELIOPATHY AND CHOROIDOPATHY IN CARCINOMATOSIS - A RARE CASE OF CANCER-ASSOCIATED RETINOPATHY, Graefe's archive for clinical and experimental ophthalmology, 235(1), 1997, pp. 59-61
Authors:
TOMIAK E
PICCART M
MIGNOLET F
SAHMOUD T
PARIDAENS R
NOOY M
BEEX L
FENTIMAN IS
MULLER A
VANDERSCHUEREN E
RUBENS RD
Citation: E. Tomiak et al., CHARACTERIZATION OF COMPLETE RESPONDERS TO COMBINATION CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - A RETROSPECTIVE EORTC BREAST GROUP-STUDY, European journal of cancer, 32A(11), 1996, pp. 1876-1887
Authors:
HUPPERETS P
WILS J
VOLOVICS L
SCHOUTEN L
FICKERS M
BRON H
SCHOUTEN H
JAGER J
DEJONG J
BEEX L
HILLEN H
BLIJHAM G
Citation: P. Hupperets et al., ADJUVANT CHEMO-HORMONAL THERAPY WITH CYCLOPHOSPHAMIDE, DOXORUBICIN AND 5-FLUOROURACIL (CAF) WITH OR WITHOUT MEDROXYPROGESTERONE ACETATE FORNODE-POSITIVE CANCER-PATIENTS - UPDATE AT 7-YEAR FOLLOW-UP, Annals of oncology, 6(1), 1995, pp. 90-91
Authors:
YEDEMA CA
KENEMANS P
VOORHORST F
BON G
SCHIJF C
BEEX L
VERSTRAETEN A
HILGERS J
VERMORKEN J
Citation: Ca. Yedema et al., CA-125 HALF-LIFE IN OVARIAN-CANCER - A MULTIVARIATE SURVIVAL ANALYSIS, British Journal of Cancer, 67(6), 1993, pp. 1361-1367